| abstract |
The invention relates to a nucleoside analog, defined according to formula (I), used as a pharmaceutical product, in which B represents an organic base, R1O represents a labile group, R2O represents a labile group or a substituted alkyloxy, aryloxy, alkyloxy group. or substituted aryloxy, and R3 is chosen from hydrogen; halide; nitro; azide; a substituted or unsubstituted amine, almine, alkoxy, aryloxy, acyloxy, sulfide, sulfone, sulfoxide, sulfonate, alkyl, alkenyl, alkynyl or heterocyclic group. |